Theravectys’ Proprietary Platform

Fully-Optimized Lentiviral Vector Vaccine Platform

20+ years of research and development on lentivirus converge in our vaccine platform, thoroughly optimized to deliver the safest and most efficient lentiviral vector vaccines.

  • Non Replicative
  • Non Pathogenic
  • Optimized Internal Promoter
  • Wide Expression Cassette enabling complex, multi-epitopic immunogen design
  • Enhanced Tropism for Dendritic Cells through VSV pseudotype envelopes
  • No Pre-existing Immunity against vector VSV pseudotypes
  • Sustained endogenous presentation of antigens
  • Prime/Boost and Single Injection Regimen
  • No Adjuvant
  • Low Production Costs due to low active dose
  • Easy Distribution through dry freezing process

  • Endogenous Antigen Processing leading to sustained Presentation through the whole Dendritic Cell (DC) Life
  • Physiological maturation of DC, no need for adjuvant
  • Long-term T-cell immunity challenged in lethal animal models (6 months after vaccination in mice)
  • Challenged against real pathogens
    • HIV: Best protection ever described in a predictive macaque/SIVmac 251 model
    • Malaria: Unique long-term sterile cellular immunity by a liver-stage vaccine
    • Zika: Long-term sterilizing protection with single injection regimen
    • MDR Tuberculosis: unrivaled BCG boost
  • Back-to-back comparisons with other vaccine candidates
    • Zika vaccine vs Plasmid & RNA vaccines
    • HIV therapeutic vaccine vs Adeno Boost & VSV vaccines
  • Straight forward approach for virally-induced cancers
  • Many on-going preclinical proof-of-concept studies in wide number of oncology indications
  • Therapeutic Melanoma Vaccine Challenge shows outstanding results
    • Lentiviral-hTERT vectors induce a stronger and long-lasting self/TERT-specific CD8 T-cell response than hTERT peptide-base vaccination.
    • H-TERT-vaccine injected after tumor grafting resulted in 90% survival rate (80+ days) & Tumor size reduction of 80%
    • Highly-promising use of melanoma poly-epitope allows for vector design correlated with specific and long-lasting CTL responses against wide range of melanoma epitopes.